Pfizer's first-in-class smoking cessation drug Champix has received approval from NICE one month before England's smoking ban comes into effect.Champix …
The former head of China's medicines regulator has been sentenced to death after being found guilty of taking bribes to …
Genzyme is to spend $345 million on acquiring specialist pharma company Bioenvision and its oncology portfolio.Genzyme already co-markets with Bioenvision …
Shares in GSK have taken another hit after news that US prescribers have turned away from diabetes drug Avandia in …
ADHD drug as effective in boys as girls, says ShireUK pharmaceutical company Shire has said that results from a study …
NICE's shortfalls have compromised public confidence in the cost and clinical-effectiveness body, the pharmaceutical industry has told MPs.The comments were …
PCTs could save the NHS more than £200 million if they can persuade more GPs to prescribe generically, according to …
GlaxoSmithKline has been forced on the defensive after its blockbuster diabetes treatment Avandia was linked to an increased risk of …
Is Medical Education the new PR?Phil Sheldon, Managing Director, Resolute Communications:Clients are increasingly waking up to the fact that medical …
Cancer Research UK has set out an ambitious list of goals to reach by 2020, which it hopes will inspire …
Two key Pfizer executives are to step down as the company continues its drive to reinvigorate itself.The departures follow the …
Pfizer has appointed PR agency Edelman to raise the European profile of its blockbuster erectile dysfunction treatment, Viagra.The company has …
Breast cancer patients may be offered chemo-free treatmentHormone therapy drugs such as AstraZeneca's Zoladex may be as effective as traditional …
Even a casual observer will have noticed the large contribution pharma makes to postgraduate medical education, both in the UK …
PR agency Ketchum has scooped a global account for Tamiflu as Roche begins further research into its use against bird …
FDA requests additional efficacy data for Dendreon's Provenge in advanced prostate cancer.Dendreon has received a complete response letter from the …
Meda and Ethypharm collaborate on NSAIDMeda and Ethypharm have signed an exclusive 15-year agreement for an innovative NSAID product which …
Merck's targeted cancer drug Erbitux has been rejected by NICE for use against head and neck cancer.The Watchdog's Final Appraisal …
The pharmaceutical industry could suffer a blow to its reputation, and could even suffer commercially, if it fails to appreciate …
Pharma revenues from primary care prescribing in England edged up three per cent in 2006, with fewer GP-led product launches …